With all the available signs suggesting that doctors are shifting away from Vytorin and Zetia as first-, or even second-line choices in cholesterol management therapy, it seems Dr. Enrico Veltri -- yes, he of "tell him to f*ck off" fame -- is still fighting the last (largely lost) war. This is from the just released issue of Circulation:
. . . .Letter by Tershakovec et al Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation". . . .
. . .Enrico P. Veltri. . .
Circulation 2009;120 e67
[Editor's Note: Here, the authors answered:]. . . .We appreciate the comments by Settergren et al on differences in the patient population and response to lipid-lowering therapies between our two studies. We agree that our patient population had lower cardiovascular risks and higher on-treatment low-density lipoprotein cholesterol (LDL-C) levels. Thus, it is possible that LDL-C lowering alone may not be the overwhelming determinant of endothelial function as observed in our study. Furthermore, the lipid-lowering response to statin monotherapy and the combination of statin and ezetimibe may differ between white and Asian patients. Regardless of these ethnic and cardiovascular risk factor differences, the LDL reduction was similar between simvastatin 40 mg and simvastatin/ezetimibe 10 mg/10 mg in our study. . . .
Link for Subscribers ($$). . .
Sincere Hat Tip: Marilyn Mann, for the heads' up!
No comments:
Post a Comment